UBS Group’s Neon Therapeutics, Inc. Common Stock NTGN Stock Holding History

UBS Group’s Portfolio NTGN Stock Details NTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-15,759	Closed	-$42K	–	8717
2020 Q1	$42K	Sell	15,759 -9,534	-38%	-$15.6K	﹤0.01%	5978
2019 Q4	$30K	Buy	25,293 +10,469	+71%	+$16.7K	﹤0.01%	6649
2019 Q3	$26K	Buy	14,824 +8,260	+126%	+$25.1K	﹤0.01%	6595
2019 Q2	$31K	Buy	6,564 +1,567	+31%	+$8.78K	﹤0.01%	6321
2019 Q1	$32K	Sell	4,997 -203	-4%	-$1.06K	﹤0.01%	5908
2018 Q4	$26K	Buy	5,200 +3,705	+248%	+$25.9K	﹤0.01%	6605
2018 Q3	$13K	Buy	1,495 +1,460	+4,171%	+$16.2K	﹤0.01%	7050
2018 Q2	$0	Buy	+35	New	+$479	﹤0.01%	8415

UBS Group's NTGN Position: Q2 2020 in Review

UBS Group sold out of Neon Therapeutics, Inc. Common Stock (NTGN) in Q2 2020, closing a stake of 15,759 shares — an estimated $42K sold.

UBS Group first reported a position in NTGN in Q2 2018 and held it in 8 quarters. The position peaked at $42K in Q1 2020. 0 funds tracked by Wall St. Rank hold NTGN as of Q2 2020.

UBS Group reported no remaining Neon Therapeutics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
UBS Group sold 15,759 Neon Therapeutics, Inc. Common Stock shares in Q2 2020, an estimated $42K.
UBS Group first reported a position in Neon Therapeutics, Inc. Common Stock in Q2 2018 and held it in 8 quarters.
UBS Group's Neon Therapeutics, Inc. Common Stock position peaked at $42K in Q1 2020.
0 funds tracked by Wall St. Rank held Neon Therapeutics, Inc. Common Stock as of Q2 2020.

Based on UBS Group's 13F filing for Q2 2020, filed 31 Jul 2020.